Related Experiment Video
Updated: Aug 11, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene therapy for coronary artery disease: The University of Michigan Program
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0644, USA.
Abstract:
Recent studies show that the cyclin dependent kinase inhibitor KIP/CIP family members function as regulators of VSMC proliferation. The prevention and treatment of cell proliferation in arteries after percutaneous intervention, represents an attractive target for gene therapy. Targeting of cell cycle regulatory proteins might inhibit cell proliferation and migration, and induce withdrawal from the cell cycle. Furthermore, these studies suggest that genetic approaches are feasible and that local expression of a regulatory gene is sufficient to abrogate lesion formation in different animal models of vascular diseases.
Insights
Cyclin-dependent kinase inhibitors (KIP/CIP family) regulate vascular smooth muscle cell (VSMC) proliferation. Gene therapy targeting these inhibitors offers a promising strategy to prevent arterial lesions after interventions.
Area of Science:
- Vascular Biology
- Molecular Medicine
- Gene Therapy
Background:
- Vascular smooth muscle cell (VSMC) proliferation is a key factor in arterial restenosis after percutaneous intervention.
- The KIP/CIP family of cyclin-dependent kinase inhibitors are known regulators of the cell cycle and VSMC growth.
Purpose of the Study:
- To investigate the role of KIP/CIP family members in regulating VSMC proliferation.
- To evaluate the potential of gene therapy targeting cell cycle regulators for preventing vascular lesion formation.
Main Methods:
- Studies involved examining the function of KIP/CIP family members in VSMC proliferation.
- Genetic approaches were employed to assess the feasibility of local gene expression in animal models of vascular disease.
Main Results:
- KIP/CIP family members were confirmed as regulators of VSMC proliferation.
- Local expression of regulatory genes was sufficient to inhibit lesion formation in animal models.
Conclusions:
- Targeting cell cycle regulatory proteins, such as KIP/CIP inhibitors, can inhibit VSMC proliferation and migration.
- Genetic approaches targeting these proteins are feasible and effective in preventing vascular lesion development.
Related Concept Videos
00:59Gene Therapy
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pharmacogenomics: Identification of New Drug Targets